CNSX:CBDN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

CBD Global Sciences Inc. engages in cannabidiol (CBD) farming, processing, and product manufacturing business. More Details


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Share Price & News

How has CBD Global Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CBDN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-20.0%

CBDN

-3.5%

CA Pharmaceuticals

-8.4%

CA Market


1 Year Return

-51.5%

CBDN

-17.4%

CA Pharmaceuticals

-60.8%

CA Market

Return vs Industry: CBDN underperformed the Canadian Pharmaceuticals industry which returned -17.2% over the past year.

Return vs Market: CBDN exceeded the Canadian Market which returned -60.7% over the past year.


Shareholder returns

CBDNIndustryMarket
7 Day-20.0%-3.5%-8.4%
30 Day-27.3%18.2%-3.0%
90 Day26.3%2.5%-26.8%
1 Year-51.5%-51.5%-17.4%-17.4%-59.2%-60.8%
3 Yearn/a-30.1%-30.8%-60.5%-64.6%
5 Yearn/a152.1%150.3%-51.9%-59.6%

Price Volatility Vs. Market

How volatile is CBD Global Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CBD Global Sciences undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether CBD Global Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as CBD Global Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is CBD Global Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

57.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CBD Global Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has CBD Global Sciences performed over the past 5 years?

-2,990.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CBDN is currently unprofitable.

Growing Profit Margin: CBDN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if CBDN's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare CBDN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CBDN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.9%).


Return on Equity

High ROE: CBDN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is CBD Global Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: CBDN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CBDN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CBDN has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CBDN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CBDN has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: CBDN is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is CBD Global Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CBDN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CBDN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CBDN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CBDN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CBDN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Brad Wyatt (51 yo)

no data

Tenure

Mr. Brad Wyatt is a Co-Founder of CBD Global Sciences Inc. and also serves as its Chief Executive Officer, President and Director. Mr. Wyatt served as Chief Executive Officer, President, and Executive Dire ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.4%.


Top Shareholders

Company Information

CBD Global Sciences Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CBD Global Sciences Inc.
  • Ticker: CBDN
  • Exchange: CNSX
  • Founded: 2018
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$5.137m
  • Shares outstanding: 34.24m
  • Website: https://www.cbdglobalsciences.com

Location

  • CBD Global Sciences Inc.
  • 225 Union Boulevard
  • Suite 350
  • Lakewood
  • Colorado
  • 80228
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CBDNCNSX (Canadian National Stock Exchange)YesCommon SharesCACADOct 2019
GS3DB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2019
CBDN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDOct 2019

Biography

CBD Global Sciences Inc. engages in cannabidiol (CBD) farming, processing, and product manufacturing business. It offers provides biomass, CBD oil, and CBD oil products under the Aethics, CannaOil, and Str ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/31 01:04
End of Day Share Price2020/10/30 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.